Johnson & Johnson (NYSE:JNJ) Coverage Initiated by Analysts at TD Cowen

Key Points

• TD Cowen initiated coverage on Johnson & Johnson with a Buy rating and a $250 price target, implying about a 5.3% upside from the prior close.
• Analyst sentiment is broadly positive — MarketBeat lists a consensus rating of "Moderate Buy" with a consensus price target of $237.57, and several firms (e.g., Citi, JPMorgan, Guggenheim) recently raised their targets.
• Shares traded at $237.47 (down ~0.4%) with a market cap of ~$572B and a P/E of 21.35; insiders have sold about 30,142 shares (~$7.36M) in the past 90 days while institutional investors own roughly 69.6% of the stock.

Stock analysts at TD Cowen assumed coverage on shares of Johnson & Johnson (NYSE:JNJ - Get Free Report) in a report released on Wednesday. The firm set a "buy" rating and a $250.00 price target on the stock. TD Cowen's price objective points to a potential upside of 5.28% from the company's previous close.

JNJ has been the subject of several other research reports. JPMorgan Chase & Co. boosted their target price on shares of Johnson & Johnson from $225.00 to $250.00 and gave the stock a "neutral" rating in a research report on Thursday, March 5th. Weiss Ratings reiterated a "buy (b)" rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. Guggenheim boosted their price objective on Johnson & Johnson from $240.00 to $244.00 and gave the company a "buy" rating in a report on Tuesday. Argus upped their price objective on Johnson & Johnson from $210.00 to $240.00 in a research note on Friday, January 23rd. Finally, Rothschild & Co Redburn increased their target price on Johnson & Johnson from $180.00 to $210.00 and gave the stock a "neutral" rating in a report on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $237.57.

Johnson & Johnson Stock Down 0.4%

Shares of Johnson & Johnson stock traded down $0.94 on Wednesday, hitting $237.47. 611,116 shares of the company's stock traded hands, compared to its average volume of 8,590,287. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $251.71. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The stock has a market cap of $571.96 billion, a P/E ratio of 21.35, a PEG ratio of 2.41 and a beta of 0.34. The firm's 50-day moving average is $240.53 and its 200 day moving average is $214.17.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The business had revenue of $24.28 billion during the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Insider Transactions at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 1,322 shares of the firm's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,251,310.02. This represents a 4.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 30,142 shares of company stock valued at $7,360,528. Insiders own 0.16% of the company's stock.

Hedge Funds Weigh In On Johnson & Johnson

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Sierra Capital LLC raised its holdings in Johnson & Johnson by 0.5% during the fourth quarter. Sierra Capital LLC now owns 8,144 shares of the company's stock worth $1,685,000 after purchasing an additional 41 shares in the last quarter. Beaird Harris Wealth Management LLC boosted its stake in Johnson & Johnson by 1.8% during the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company's stock valued at $501,000 after purchasing an additional 42 shares in the last quarter. Broadleaf Partners LLC increased its position in shares of Johnson & Johnson by 0.6% during the 4th quarter. Broadleaf Partners LLC now owns 7,348 shares of the company's stock valued at $1,521,000 after purchasing an additional 43 shares during the period. Jessup Wealth Management Inc raised its stake in shares of Johnson & Johnson by 0.6% in the 4th quarter. Jessup Wealth Management Inc now owns 7,574 shares of the company's stock worth $1,567,000 after buying an additional 44 shares in the last quarter. Finally, Plancorp LLC lifted its holdings in shares of Johnson & Johnson by 0.3% in the fourth quarter. Plancorp LLC now owns 15,889 shares of the company's stock valued at $3,288,000 after buying an additional 45 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Citi raised its price target to $285 and kept a Buy rating, signaling sizable upside from current levels which is drawing buying interest. Citigroup Raises PT to $285
• Positive Sentiment: Guggenheim nudged its target to $244 and kept a Buy rating — another analyst endorsement supporting demand for the shares. Guggenheim Raises PT to $244
• Positive Sentiment: TD Cowen reiterated a Buy with a $250 target, adding to the analyst support narrative that’s boosting sentiment. TD Cowen Buy Rating
• Positive Sentiment: Product/pipeline progress: J&J received CE mark and launched Varipulse Pro in Europe (next‑gen PFA catheter with faster ablation), and reported specialty therapy updates including a permanent US reimbursement code for INLEXZO and positive ICOTYDE data — these are concrete near‑term commercial catalysts. Varipulse Pro Launch
• Neutral Sentiment: Market commentary and stock‑selection pieces are highlighting J&J as a low‑volatility, dividend‑growth blue chip and a name “near buy zone,” which tends to support steady demand from income and momentum investors. Low‑Volatility Blue Chip Coverage
• Neutral Sentiment: Aggregated analyst‑call roundups and consensus ratings (e.g., “Moderate Buy”) keep JNJ on investors’ radar but don’t change fundamentals immediately. Analyst Research Calls Roundup
• Negative Sentiment: Not all upgrades imply big near‑term upside — Guggenheim’s new $244 target implies only a small premium to current levels, highlighting that some analyst moves are modest and valuation could limit immediate gains. Guggenheim PT Context

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.